MRNY gained roughly 152% over the trailing 30 days, with nearly all of that advance occurring in a single session following a landmark clinical catalyst for Moderna (MRNA) . The fund is an actively managed single-stock covered-call strategy, meaning its upside participation in MRNA is capped relative to the underlying stock's move.
GDXU advanced roughly 143% over the trailing 30 days, climbing from about $81.92 to $199.03 per note, as a powerful gold-mining rally was amplified by three-times daily leverage. Over the past quarter the note rose about 26% , but the path was extraordinarily volatile, with a decline into the mid-$60s in mid-July before the sharp rebound.
CRCG surged roughly +105% over the last 30 days, from about $8.05 to $16.52, as 2x daily leverage amplified a rebound in underlying Circle Internet Group (CRCL) shares. Over the trailing quarter the fund remains down about 38% , reflecting a sharp drawdown earlier in the period followed by a rapid recovery.
AXTX, a 2x leveraged ETF tracking AXT Inc. (AXTI), gained +5.33% to $7.51 during the regular session on Aug 25 versus the prior close of $7.13. The advance reflects roughly double the underlying AXTI's +3.12% gain, amplified by the fund's daily 2x leverage.
BMNU, a 2x leveraged ETF tracking Bitmine Immersion Technologies (BMNR), closed up +5.73% at $20.11 versus the prior session's $19.02 during regular market hours. The gain reflects its 2x exposure to BMNR, which rose +2.82% to $24.82 on the same day.
USO fell -4.62% to $126.10 during regular trading, sliding from the prior session's $132.21 close. The drop tracks WTI crude, which tumbled more than -3% to roughly $82 per barrel as geopolitical risk premium unwound.
SMCI is up +8.81% during the regular session, trading near $38.27 versus Friday's close of $35.17. The primary catalyst: Cisco expanded its "Secure AI Factory with NVIDIA" to include Supermicro's high-density liquid- and air-cooled servers.
AMIX surged +46.74% to $7.88, up from the prior session's close of $5.37, with the gain extending through premarket and regular trading hours. The move followed the company's announcement of a $4.9 million warrant inducement agreement, priced at a premium under Nasdaq rules.
Sionna Therapeutics (SION) shares have fallen roughly 86% over the last 30 days, driven almost entirely by a single-day collapse following disappointing clinical trial data. The decline followed the failure of SION-719, the company's lead cystic fibrosis candidate, in a Phase 2a proof-of-concept trial announced in August 2026.
YARW shares have gained roughly 55% over the last 30 days, climbing from about $25.45 to near $39.50. The advance followed Yarrow Bioscience's Nasdaq debut after completing its merger with VYNE Therapeutics in late July 2026.
TNMG jumped +37.5% during regular trading to roughly $0.55, versus a $0.40 prior-session close. The catalyst was news that the Nasdaq Hearings Panel granted the company continued listing on the Nasdaq Capital Market, removing the immediate delisting overhang.
DAIC is up +78.61%, trading near $3.09 in the regular session after closing Monday at $1.73. The move extends Monday's +306% surge, driven by momentum and a short-squeeze-style continuation in a heavily shorted microcap.
AIXI surged roughly +187% to about $1.32 intraday versus a prior close of $0.46, extending an earlier premarket gain of nearly +90%. The advance occurred during regular trading hours, with premarket follow-through, on sharply elevated volume.
COKE shares recently traded near $192, leaving roughly a 30% gap to the widely discussed $250 price level. $250 would mark a new all-time high, above the stock's previous record close around $219.65 set in March 2026.
FBDT closed down -48.62% (-$1.94) to $2.05 from a prior close of $3.99, during regular Nasdaq session trading. The decline occurred in market hours, not premarket or after-hours.
SWVL surged roughly +62.4% during regular market hours, jumping from a prior close of $1.49 to about $2.42 intraday on heavy volume. The primary catalyst was the announcement of a $13 million PIPE led by Coefficient LP, backed by the Sawiris family, which will become the company's largest institutional shareholder.
GRRR is down -12.26% to about $13.89 during Tuesday's regular session, after closing at $15.83 on Monday. The selloff follows H1 2026 results: revenue nearly doubled (+99% to $78.4M), but an adjusted loss of $0.58/share badly missed estimates and reversed a year-ago profit.
SLQT is down -28.21% (about -$0.22) to roughly $0.56, extending a premarket slide into the regular session. Catalyst: fiscal Q4 2026 results missed on both lines — a $0.19/share loss versus a -$0.15 consensus and revenue of $321.7M versus ~$345.3M expected.
DKS shares plunged about -19.51% to roughly $144.34 in the latest session, down from Monday's close of $179.33, with the decline starting in premarket trading. The selloff followed a Q2 miss: adjusted EPS of $3.53 versus a $3.76-$3.78 consensus, and revenue of $5.59B below the ~$5.64B estimate.
DKS shares plunged about -19.51% to roughly $144.34 in the latest session, down from Monday's close of $179.33, with the decline starting in premarket trading. The selloff followed a Q2 miss: adjusted EPS of $3.53 versus a $3.76-$3.78 consensus, and revenue of $5.59B below the ~$5.64B estimate.